Biogen’s Lowest Diranersen Dose Wins; Failed Dose Response Forces Phase III Rethink

Biogen has revealed mixed CELIA Phase II trial data for diranersen at AAIC 2026. The lowest 60 mg dose slowed clinical decline more than either 115 mg arm, although CELIA aimed to show greater benefit at higher doses. Consequently, the